Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025

Global Non Alcoholic Steatohepatitis NASH Market Report 2024

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025 – By Type (Solid, Liquid), By Product (Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products), By Disease Cause (Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity), By Sales Channel (Hospital Pharmacy, Retail Pharmacy, Online Provider), By Application (Oral, Parenteral) – Market Size, Trends, And Global Forecast 2025-2034

Name: Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2025

Proud Members Of

Non-Alcoholic Steatohepatitis (NASH) Market Definition

Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by inflammation of the liver and can proceed to cirrhosis and liver failure.

The main types of non-alcoholic steatohepatitis (NASH) are solid and liquid. Solid is primarily created as crystalline solid forms that are sold as tablets for oral consumption, due to its excellent purity and durability. The products involved are vitamin E and pioglitazone, ocaliva, elafibranor, selonsertib, and cenicriviroc, and others that are used for different disease causes such as hypertension, heart disease, high blood lipid, type 2 diabetes, obesity, and sold by the hospital pharmacy, retail pharmacy, online providers. It includes oral and parenteral applications.

Non-Alcoholic Steatohepatitis (NASH) Market Segmentation

The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented –

1) By Type: Solid, Liquid

2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products

3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider

5) By Application: Oral, Parenteral

Subsegments:

1) By Solid: Tablets, Capsules, Other Solid Dosage Forms

2) By Liquid: Oral Solutions, syrups, Injectable Solutions, Other Liquid Dosage Forms

Non-Alcoholic Steatohepatitis (NASH) Market Size and growth rate 2025 to 2029: Graph

Non-Alcoholic Steatohepatitis (NASH) Market Size 2025 And Growth Rate

The non-alcoholic steatohepatitis (NASH) market size has grown exponentially in recent years. It will grow from $4.5 billion in 2024 to $6.13 billion in 2025 at a compound annual growth rate (CAGR) of 36.1%. The growth in the historic period can be attributed to rising prevalence of NASH, obesity epidemic, growing awareness and diagnoses, shift in lifestyle and dietary patterns, healthcare infrastructure development.

Non-Alcoholic Steatohepatitis (NASH) Market Growth Forecast

The non-alcoholic steatohepatitis (NASH) market size is expected to see exponential growth in the next few years. It will grow to $19.07 billion in 2029 at a compound annual growth rate (CAGR) of 32.8%. The growth in the forecast period can be attributed to advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, government support and regulations. Major trends in the forecast period include focus on lifestyle interventions and patient education, increased collaboration in clinical research, regulatory advancements and pathway designations, integration of artificial intelligence in diagnosis and monitoring.

Book your 30 minutes free consultation with our research experts

Non-Alcoholic Steatohepatitis (NASH) Market Driver: The Growing Demand For NASH Treatment Amid Obesity Epidemic

The rising cases of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market going forward. Obesity is an aberrant or excessive fat build-up that poses a health concern, as well as body weight that is higher than what is deemed healthy or typical for a person of a specific height. As non-alcoholic fatty liver disease has become more prevalent due to the rising obesity pandemic, NASH may become the most widespread cause of severe liver disease in the ensuing decades, therefore, driving need for NASH treatment and related drugs. For instance, in March 2024, according to the World Health Organization (WHO), a UK-based international public health organization, in 2022, approximately 2.5 billion adults aged 18 and older were classified as overweight, with 890 million of them living with obesity. Therefore, the rise in the cases of obesity will drive the growth of the non-alcoholic steatohepatitis (NASH) market.

Non-Alcoholic Steatohepatitis (NASH) Market Driver: Geriatric Population Fuels Non-Alcoholic Steatohepatitis (NASH) Market Growth

The increasing geriatric population is driving the demand for the non-alcoholic steatohepatitis (NASH) market going forward. The geriatric population refers to individuals aged 65 and older, characterized by specific healthcare needs associated with aging. The development and advancement of treatments in the non-alcoholic steatohepatitis (NASH) market contribute significantly to improving the overall health outcomes for the geriatric population, addressing a prevalent liver-related condition in aging individuals. For instance, in October 2022, according to the World Health Organization, a US-based specialized health agency, globally, 1 in 6 individuals would be 60 or older by 2030 and is expected to reach 2.1 billion elderly people by 2050. Therefore, the increasing geriatric population drives the growth of the Non-Alcoholic Steatohepatitis (NASH) market.

Global Non-Alcoholic Steatohepatitis (NASH) Market Major Players

Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.

Global Non-Alcoholic Steatohepatitis (NASH) Market Trend: Innovative Therapeutic Approaches for Liver Health

Major companies operating in the non-alcoholic steatohepatitis (NASH) market are developing thyroid hormone receptor-beta (THR-beta) agonists to enhance liver metabolism, reduce liver fat accumulation, and improve liver function. Thyroid hormone receptor-beta (THR-beta) agonists are compounds that selectively activate the thyroid hormone receptor-beta subtype, which is a key receptor involved in the regulation of metabolism, growth, and development. For instance, in March 2024, the Food and Drug Administration, a US-based regulatory body, approved Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist as the first treatment for adults with noncirrhotic NASH with moderate to advanced liver scarring (fibrosis). By selectively activating the THR-beta receptor, Rezdiffra helps regulate lipid metabolism, leading to a reduction in intrahepatic triglycerides and overall liver fat accumulation.

Global Non-Alcoholic Steatohepatitis (NASH) Market Trend: Unveiling Therapeutic Breakthroughs For NASH Treatment

Major companies in the non-alcoholic steatohepatitis (NASH) market are focusing on developing innovative product, such as a thyroid hormone receptor (THR)-ß selective agonist designed to target key underlying causes of non-alcoholic steatohepatitis. The thyroid hormone receptor is a protein that, upon binding with thyroid hormones, regulates gene expression and plays a crucial role in various physiological processes. For instance, in July 2023, Madrigal Pharmaceuticals, Inc., a US-based clinical-stage biopharmaceutical company that develops and commercializes drugs, completed the submission of a New Drug Application seeking accelerated approval of Resmetirom for the treatment of NASH with liver fibrosis. This product, with key features such as once-daily oral therapy and liver-directed action, targets hepatic steatosis, inflammation, and hepatocellular injury in non-alcoholic steatohepatitis (NASH) with liver fibrosis. Its Breakthrough Therapy designation by the FDA and a comprehensive clinical development program, including Phase 3 trials, underscore its potential to address unmet medical needs, offering a promising advancement in the treatment landscape for NASH with liver fibrosis.

Non-Alcoholic Steatohepatitis (NASH) Market Merger And Acquisition: Advanz Pharma Corp. Limited's Strategic Acquisition Of Intercept Pharmaceuticals Inc

In July 2022, Advanz Pharma Corp. Limited, a UK-based pharmaceutical company acquired Intercept Pharmaceuticals Inc for an undisclosed amount. With this deal, Advanz Pharma aims to have a significant presence in the treatment of rare diseases by including the ex-U.S. rights to the orphan medicine Ocaliva (obeticholic acid), which is used to treat primary biliary cholangitis (PBC). Intercept Pharmaceuticals Inc is a US-based biopharmaceutical company focused on creating and marketing cutting-edge therapies for the treatment of progressive non-viral liver disorders.

Regional Outlook For The Global Non-Alcoholic Steatohepatitis (NASH) Market

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (NASH) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-alcoholic steatohepatitis (NASH) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-Alcoholic Steatohepatitis (NASH) Market?

The non-alcoholic steatohepatitis (NASH) market consists of sales of drugs that are used for the treatment of non-alcoholic fatty liver diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Non-Alcoholic Steatohepatitis (NASH) Industry?

The non-alcoholic steatohepatitis (NASH) market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis (NASH) market statistics, including non-alcoholic steatohepatitis (NASH) industry global market size, regional shares, competitors with non-alcoholic steatohepatitis (NASH) market share, detailed non-alcoholic steatohepatitis (NASH) market segments, market trends, and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis (NASH) industry. This non-alcoholic steatohepatitis (NASH) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Non-Alcoholic Steatohepatitis (NASH) Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$6.13 billion
Revenue Forecast In 2034	$19.07 billion
Growth Rate	CAGR of 32.8% from 2024 to 2033
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Type: Solid, Liquid 2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products 3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity 4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider 5) By Application: Oral, Parenteral Subsegments: 1) By Solid: Tablets, Capsules, Other Solid Dosage Forms 2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Non-Alcoholic Steatohepatitis (NASH) Market Characteristics

3. Non-Alcoholic Steatohepatitis (NASH) Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis (NASH) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Non-Alcoholic Steatohepatitis (NASH) Growth Analysis And Strategic Analysis Framework

5.1. Global Non-Alcoholic Steatohepatitis (NASH) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Non-Alcoholic Steatohepatitis (NASH) Market Growth Rate Analysis

5.4. Global Non-Alcoholic Steatohepatitis (NASH) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Non-Alcoholic Steatohepatitis (NASH) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Non-Alcoholic Steatohepatitis (NASH) Total Addressable Market (TAM)

6. Non-Alcoholic Steatohepatitis (NASH) Market Segmentation

6.1. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Solid

Liquid

6.2. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Vitamin E and Pioglitazone

Ocaliva

Elafibranor

Selonsertib and Cenicriviroc

Other Products

6.3. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hypertension

Heart Disease

High Blood Lipid

Type 2 Diabetes

Obesity

6.4. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Provider

6.5. Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Parenteral

6.6. Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Solid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Tablets

Capsules

Other Solid Dosage Forms

6.7. Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Liquid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral Solutions

Syrups

Injectable Solutions

Other Liquid Dosage Forms

7. Non-Alcoholic Steatohepatitis (NASH) Market Regional And Country Analysis

7.1. Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market

8.1. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Alcoholic Steatohepatitis (NASH) Market

9.1. China Non-Alcoholic Steatohepatitis (NASH) Market Overview

9.2. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Alcoholic Steatohepatitis (NASH) Market

10.1. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Alcoholic Steatohepatitis (NASH) Market

11.1. Japan Non-Alcoholic Steatohepatitis (NASH) Market Overview

11.2. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Alcoholic Steatohepatitis (NASH) Market

12.1. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market

13.1. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Alcoholic Steatohepatitis (NASH) Market

14.1. South Korea Non-Alcoholic Steatohepatitis (NASH) Market Overview

14.2. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market

15.1. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview

15.2. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Alcoholic Steatohepatitis (NASH) Market

16.1. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Alcoholic Steatohepatitis (NASH) Market

17.1. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Alcoholic Steatohepatitis (NASH) Market

18.1. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Alcoholic Steatohepatitis (NASH) Market

19.1. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Alcoholic Steatohepatitis (NASH) Market

20.1. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market

21.1. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market Overview

21.2. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Alcoholic Steatohepatitis (NASH) Market

22.1. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Alcoholic Steatohepatitis (NASH) Market

23.1. North America Non-Alcoholic Steatohepatitis (NASH) Market Overview

23.2. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Alcoholic Steatohepatitis (NASH) Market

24.1. USA Non-Alcoholic Steatohepatitis (NASH) Market Overview

24.2. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Alcoholic Steatohepatitis (NASH) Market

25.1. Canada Non-Alcoholic Steatohepatitis (NASH) Market Overview

25.2. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Alcoholic Steatohepatitis (NASH) Market

26.1. South America Non-Alcoholic Steatohepatitis (NASH) Market Overview

26.2. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Alcoholic Steatohepatitis (NASH) Market

27.1. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Alcoholic Steatohepatitis (NASH) Market

28.1. Middle East Non-Alcoholic Steatohepatitis (NASH) Market Overview

28.2. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Alcoholic Steatohepatitis (NASH) Market

29.1. Africa Non-Alcoholic Steatohepatitis (NASH) Market Overview

29.2. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape And Company Profiles

30.1. Non-Alcoholic Steatohepatitis (NASH) Market Competitive Landscape

30.2. Non-Alcoholic Steatohepatitis (NASH) Market Company Profiles

30.2.1. NGM Biopharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.3. AstraZeneca plc. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. GlaxoSmithKline plc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

31. Non-Alcoholic Steatohepatitis (NASH) Market Other Major And Innovative Companies

31.1. The Takeda Pharmaceutical Company Limited

31.2. Gilead Sciences Inc.

31.3. Novo Nordisk A/S

31.4. Genfit SA

31.5. Cadila Pharmaceuticals Ltd.

31.6. Intercept Pharmaceuticals Inc.

31.7. Enanta Pharmaceuticals Inc.

31.8. Blade Therapeutics Inc.

31.9. Galmed Pharmaceuticals Inc.

31.10. Immuron Limited

31.11. Terns Pharmaceuticals Inc.

31.12. Tobira Therapeutics Inc.

31.13. Arena Pharmaceuticals Inc.

31.14. Galectin Therapeutics Inc.

31.15. Viking Therapeutics

32. Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis (NASH) Market

34. Recent Developments In The Non-Alcoholic Steatohepatitis (NASH) Market

35. Non-Alcoholic Steatohepatitis (NASH) Market High Potential Countries, Segments and Strategies

35.1 Non-Alcoholic Steatohepatitis (NASH) Market In 2029 - Countries Offering Most New Opportunities

35.2 Non-Alcoholic Steatohepatitis (NASH) Market In 2029 - Segments Offering Most New Opportunities

35.3 Non-Alcoholic Steatohepatitis (NASH) Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Solid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Liquid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: NGM Biopharmaceuticals Inc. Financial Performance

Table 79: Novartis AG Financial Performance

Table 80: AstraZeneca plc. Financial Performance

Table 81: GlaxoSmithKline plc. Financial Performance

Table 82: F. Hoffmann-La Roche AG Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Sales Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Solid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Non-Alcoholic Steatohepatitis (NASH) Market, Sub-Segmentation Of Liquid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Non-Alcoholic Steatohepatitis (NASH) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Non-Alcoholic Steatohepatitis (NASH) Market, Segmentation By Disease Cause, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: NGM Biopharmaceuticals Inc. Financial Performance

Figure 79: Novartis AG Financial Performance

Figure 80: AstraZeneca plc. Financial Performance

Figure 81: GlaxoSmithKline plc. Financial Performance

Figure 82: F. Hoffmann-La Roche AG Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

The Microbiome Market Share, Market Size, And Growth Rate 2022

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the hormonal contraceptives market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the kidney cancer drugs market research report 2022 with industry size, share, segments and market growth

Alcoholic - Beverages Global Market Report 2025 – By Type (Beer, Wine And Brandy, Spirits), By Category (Mass, Premium), By Distribution Channel (Off-Trade Channels, On-Trade Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Grain Products Global Market Report 2025 – By Type (Flour, Rice And Malt, Other Grain Products), By Price Range (Premium, Mid, Low), By Distribution Channel (Supermarkets/Hypermarkets, Convenience Stores, E-Commerce, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Grain Farming Global Market Report 2025 – By Type (Dry Pea And Bean Farming, Wheat Farming, Other Grain Farming), By Farming Process (Organic Grain Farming, Traditional Farming), By Application (Food And Beverages, Fodder, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Grain Processing Equipment Global Market Report 2025 – By Machine (Pre Processing, Processing), By Technology (Automatic, Semi-Automatic), By Application (Cleaning, Grading, Handling, Coaters, Dryers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Organic Grain Farming Global Market Report 2025 – By Type (Organic Corn, Organic Wheat, Other Types), By Farming Type (Pure Organic Farming, Integrated Organic), By End-User (Household, Commercial, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Non Alcoholic - Beverages Global Market Report 2025 – By Type (Coffee And Tea, Soft Drink And Ice), By Distribution Channel (Off-Trade Channels, On-Trade Channels), By Category (Mass, Premium) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Ethyl Alcohol And Other Basic Organic Chemical Global Market Report 2025 – By Type (Synthetic Sweeteners, Plasticizers, Ethyl Alcohol, Silicone (except Resins), Fatty Acids, Gum and Wood Chemicals), By Grade (Food Grade, Industrial Grade, Cosmetics Grade), By End User Industry (Chemical Industry, Coating And Printing Industry, Electronics Industry, Food And Pharmaceutical Industry, Other End-User Industries) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Food And Beverages Global Market Report 2025 – By Type (Alcoholic – Beverages, Non-Alcoholic – Beverages, Grain Products, Bakery And Confectionery, Frozen, Other Foods Products), By Nature (Organic, Conventional), By Distribution Channel (Supermarkets/Hypermarkets, Convenience Stores, E-Commerce, Other Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Non-Alcoholic Steatohepatitis (NASH) market?

Non-alcoholic steatohepatitis (NASH) is a severe case of fatty liver disease that is characterized by inflammation of the liver and can proceed to cirrhosis and liver failure. For further insights on the Non-Alcoholic Steatohepatitis (NASH) market, request a sample here

How will the Non-Alcoholic Steatohepatitis (NASH) market drivers and restraints affect the market dynamics? What forces will shape the Non-Alcoholic Steatohepatitis (NASH) industry going forward?

The Non-Alcoholic Steatohepatitis (NASH) market major growth driver - The Growing Demand For NASH Treatment Amid Obesity Epidemic. For further insights on the Non-Alcoholic Steatohepatitis (NASH) market, request a sample here

What is the forecast market size or the forecast market value of the Non-Alcoholic Steatohepatitis (NASH) market?

The Non-Alcoholic Steatohepatitis (NASH) market size has grown strongly in recent years. The non-alcoholic steatohepatitis (NASH) market size has grown exponentially in recent years. It will grow from $4.5 billion in 2024 to $6.13 billion in 2025 at a compound annual growth rate (CAGR) of 36.1%. The growth in the historic period can be attributed to rising prevalence of NASH, obesity epidemic, growing awareness and diagnoses, shift in lifestyle and dietary patterns, healthcare infrastructure development. The non-alcoholic steatohepatitis (NASH) market size is expected to see exponential growth in the next few years. It will grow to $19.07 billion in 2029 at a compound annual growth rate (CAGR) of 32.8%. The growth in the forecast period can be attributed to advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, government support and regulations. Major trends in the forecast period include focus on lifestyle interventions and patient education, increased collaboration in clinical research, regulatory advancements and pathway designations, integration of artificial intelligence in diagnosis and monitoring. For further insights on the Non-Alcoholic Steatohepatitis (NASH) market, request a sample here

How is the Non-Alcoholic Steatohepatitis (NASH) market segmented?

The non-alcoholic steatohepatitis (NASH) market covered in this report is segmented –
1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms For further insights on the Non-Alcoholic Steatohepatitis (NASH) market, request a sample here

Which region has the largest share of the Non-Alcoholic Steatohepatitis (NASH) market? What are the other regions covered in the report?

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Non-Alcoholic Steatohepatitis (NASH) market, request a sample here.

Who are the major players in the Non-Alcoholic Steatohepatitis (NASH) market?

What are the key trends in the Non-Alcoholic Steatohepatitis (NASH) market?

Major trends in the Non-Alcoholic Steatohepatitis (NASH) market include Innovative Therapeutic Approaches for Liver Health. For further insights on the Non-Alcoholic Steatohepatitis (NASH) market, request a sample here.

What are the major opportunities in the Non-Alcoholic Steatohepatitis (NASH) market? What are the strategies for the Non-Alcoholic Steatohepatitis (NASH) market?

For detailed insights on the major opportunities and strategies in the Non-Alcoholic Steatohepatitis (NASH) market, request a sample here.

How does the Non-Alcoholic Steatohepatitis (NASH) market relate to the overall economy and other similar markets?

For detailed insights on Non-Alcoholic Steatohepatitis (NASH)'s relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Non-Alcoholic Steatohepatitis (NASH) industry?

For detailed insights on the mergers and acquisitions in the Non-Alcoholic Steatohepatitis (NASH) industry, request a sample here.

What are the key dynamics influencing the Non-Alcoholic Steatohepatitis (NASH) market growth? SWOT analysis of the Non-Alcoholic Steatohepatitis (NASH) market.

For detailed insights on the key dynamics influencing the Non-Alcoholic Steatohepatitis (NASH) market growth and SWOT analysis of the Non-Alcoholic Steatohepatitis (NASH) industry, request a sample here.